Brief: Biotec Pharmacon Q4 EBITDA Rises To NOK 4.6 Million

Arcticzymes Technologies ASA

30/01/2020 06:03

Jan 30 (Reuters) - Biotec Pharmacon ASA  BIOTEC.OL :
    * BIOTEC PHARMACON Q4 2019 REPORT
    * Q4 POSITIVE EBITDA WITH NOK 4.6 MILLION (Q4 2018: NOK 1.8
MILLION)
    * Q4 GROSS PROFIT FOR GROUP IMPROVED 28% TO NOK 18.1 MILLION
    * Q4 GROSS PROFIT FOR GROUP IMPROVED 28% TO NOK 18.1 MILLION
(Q4
2018: NOK 14.2MILLION)
    * ARCTICZYMES HAD Q4 SALES OF NOK 16.2 MILLION GROWING BY
52%
    * RECENT DECISION TO REDIRECT OUR MAIN STRATEGIC FOCUS
TOWARD
ARCTICZYMES WILL ONLY CATALYSE GROWTH POTENTIAL AND
PROFITABILITY OF COMPANY EVEN MORE AS WE MOVE INTO 2020 AND
BEYOND - CEO

Source text for Eikon:  ID:nWkr4KPjYj 
Further company coverage:  BIOTEC.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))